Cell Therapy: A Therapeutic Alternative to Treat Focal Cartilage Lesions

Gimeno, María José Pena; Maneiro, Emilia; Rendal, E.; Ramallal, M.; Sanjurjo, Luis A.; Blanco, F.J.

doi:10.1016/j.transproceed.2005.09.122

Cited by 16 publications

(13 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…STRO‐1 and CD146 were expressed in the membranes of hPDLCs, suggesting that hPDLCs were consistent with mesenchymal cell characteristics. CD34 is a marker of hematopoietic cells, and the extremely low expression of CD34 was consistent with mesenchymal cell characteristics . Alizarin red staining, Alcian blue staining, and oil red O staining were performed to detect the multipotential differentiation of the hPDLCs.…”

Section: Resultsmentioning

confidence: 99%

“…CD34 is a marker of hematopoietic cells, and the extremely low expression of CD34 was consistent with mesenchymal cell characteristics. 29 Alizarin red staining, Alcian blue staining, and oil red O staining were performed to detect the multipotential differentiation of the hPDLCs. The results showed that hPDLCs had multidirectional differentiation ability-osteogenic, chondrogenic, and adipogenic differentiation ( Figure 1J-L).…”

Section: Morphology and Characterization Of Hpdlcsmentioning

confidence: 99%

See 1 more Smart Citation

LIPUS inhibited the expression of inflammatory factors and promoted the osteogenic differentiation capacity of hPDLCs by inhibiting the NF‐κB signaling pathway

Liu

Zhou

et al. 2019

J of Periodontal Research

View full text Add to dashboard Cite

Background and Objectives As a chronic infectious disease, periodontitis could lead to tooth and bone loss. Low‐intensity pulsed ultrasound (LIPUS) is a safe, noninvasive treatment method to effectively inhibit inflammation and promote bone differentiation. However, the application of LIPUS in curing periodontitis is still rare. Our study aimed to explore the ability of LIPUS to inhibit inflammatory factors and promote the osteogenic differentiation capacity of human periodontal ligament cells (hPDLCs), and its underlying mechanism. Material and Methods Human periodontal ligament cells were obtained and cultured from the premolar tissue samples for experiments. First, hPDLCs were treated for 24 hours using lipopolysaccharide (LPS) and then exposed to LIPUS (10 mW/cm2, 30 mW/cm2, 60 mW/cm2, and 90 mW/cm2) to determine the appropriate intensity to inhibit expression of the inflammatory factors interleukin‐6 (IL‐6) and interleukin‐8 (IL‐8) expression. The expression of IL‐6 and IL‐8 was detected by real‐time PCR and enzyme‐linked immunosorbent assay. The safety of the most appropriate intensity of LIPUS was tested by a cell counting kit 8 test and an apoptosis assay. Then, LPS‐induced hPDLCs were treated in osteogenic medium for 7‐21 days with or without LIPUS (90 mW/cm2, 30 min/d) stimulation. The osteogenic genes RUNX2, OPN, OSX, and OCN were measured by real‐time PCR. Additionally, osteogenic differentiation capacity was determined using alkaline phosphatase (ALP) staining, ALP activity analysis, and Alizarin red staining. The activity of the nuclear factor‐kappa B (NF‐κB) signaling pathway was determined by western blotting, real‐time PCR, immunofluorescence, and pathway blockade assays. Results Lipopolysaccharide significantly upregulated the production and gene expression of IL‐6 and IL‐8, while LIPUS stimulation significantly inhibited IL‐6 and IL‐8 expression in an intensity‐dependent manner. LIPUS (90 mW/cm2) was chosen as the most appropriate intensity, and there was no detrimental influence on cell proliferation and status with or without osteogenic medium. In addition, consecutive stimulation with LIPUS (90 mW/cm2) for 30 min/d for 7 days could also inhibit IL‐6 and IL‐8 gene expression, upregulate the expression of the osteogenesis‐related genes RUNX2, OPN, OSX, and OCN, and promote osteogenic differentiation capacity in osteogenic medium in inflamed hPDLCs. The NF‐κB signaling pathway was inhibited with LIPUS (90 mW/cm2) via inhibition of the phosphorylation of IκBα and the translocation of p65 into the nucleus in inflamed hPDLCs. Additional investigations of the NF‐κB inhibitor, BAY 11‐7082, revealed that LIPUS (90 mW/cm2) acted similarly to BAY 11‐7802 to inhibit the NF‐κB signaling pathway and increase osteogenesis‐related genes and promote the osteogenic differentiation capacity of inflamed hPDLCs. Conclusion Low‐intensity pulsed ultrasound (90 mW/cm2) stimulation could be a safe method to inhibit IL‐6 and IL‐8 in hPDLCs by inhibiting the NF‐κB signaling pathway. The effect of LIPUS (90 mW...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Morphology and Characterization Of Hpdlcsmentioning

confidence: 99%

LIPUS inhibited the expression of inflammatory factors and promoted the osteogenic differentiation capacity of hPDLCs by inhibiting the NF‐κB signaling pathway

Liu

Zhou

et al. 2019

J of Periodontal Research

View full text Add to dashboard Cite

show abstract

“…The cultures were fed weekly by removing 75% of the medium and adding fresh medium to make up the same volume. After the cultivated cells became adherent, stromal cell shaped, positive for mesenchymal stem cell markers (CD44 and CD90), and negative for hematopoietic markers (CD34, CD45, and CD11b), they were used as stroma cells (26). In experiments inducing B7.2 and B7-H2 expression, mononuclear cells were cultured in complete medium on autologous stroma cells for 3 wk or with TNF-a (500 units/mL) for 2 d.…”

Section: Translational Relevancementioning

confidence: 99%

Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage

Yamashita

Tamura²,

Satoh

et al. 2009

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Once these questions are answered, both in vitro and in vivo, the use of allogenic cells should be considered. [112][113][114], cord blood [115], periosteum [116], lungs [117], adipose tissue [118,119], amniotic fluid [120,121], the bloodstream [121] and synovium [122,123]. These cells share phenotypical and/or functional characteristics of bone marrow MSCs, but their origin and their functions in these various tissues are not completely understood.…”

Section: Elucidating the Immunological Properties Of Mscsmentioning

confidence: 99%

Mesenchymal Stem Cells in Bone and Cartilage Repair: Current Status

Vilquin

Rosset

2006

Regenerative Med.

View full text Add to dashboard Cite

The progression of rheumatoid pathologies, degenerative diseases, traumatologies, and their cortege of increasing medical, social and economical needs, has mandated the development of tissue repair and engineering technologies in orthopedic medicine. Mesenchymal stem cells (MSCs) are multipotent cells that can be extracted from large and relatively easily accessible compartments of the body, especially the bone marrow, and such cells are able to differentiate into adipogenic, chondrogenic and osteogenic precursors. The concept of using MSCs to repair tissues has progressively evolved, and the goal of cell-mediated therapy is to prolong the natural physiological abilities of healing, or substitute them, when these are lacking, failing or progressing too slowly. In recent years, the first clinical trials on the utility of MSCs, with or without scaffolds and/or growth factors, have been initiated. In this review, the authors focus on findings from preclinical research, clinical trials and case reports involving bone and cartilage repairs. New perspectives are considered regarding uses of cell types, cell delivery approaches and growth factors. They also consider the stringent conditions, constraints and considerations necessary to take cell-mediated therapy from bench to bedside.

show abstract

Cell Therapy: A Therapeutic Alternative to Treat Focal Cartilage Lesions

Cited by 16 publications

References 9 publications

LIPUS inhibited the expression of inflammatory factors and promoted the osteogenic differentiation capacity of hPDLCs by inhibiting the NF‐κB signaling pathway

LIPUS inhibited the expression of inflammatory factors and promoted the osteogenic differentiation capacity of hPDLCs by inhibiting the NF‐κB signaling pathway

Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage

Mesenchymal Stem Cells in Bone and Cartilage Repair: Current Status

Contact Info

Product

Resources

About